Eloralintide vs Retatrutide: Amylin Agonist vs Triple Agonist (2026)

Reviewed by

Brandon Johnson — Certified Personal Trainer, Nutrition Coach & Peptide Research Consultant

Brandon Johnson is a certified personal trainer, nutrition coach, and peptide research consultant with a background in kinesiology and over 15 years of experience in fitness and wellness. He reviews all PSPeptides educational content for scientific accuracy and practical relevance.

Eloralintide vs retatrutide comes down to two Lilly peptides with different mechanisms and different clocks: at 48 weeks in adults without type 2 diabetes, eloralintide 9 mg produced a −20.1% body-weight change (placebo −0.4%) in its Phase 2 trial, retatrutide 12 mg produced −24.2% (placebo −2.1%) in its own 48-week Phase 2 trial, and retatrutide has since reached −28.3% at 80 weeks in Phase 3. Those three figures come from three separate trials, so they are indicative, not head-to-head.

Both molecules are investigational and neither is approved by any regulator as of October 2026. Retatrutide is further along the calendar, with Lilly planning a BLA submission in the first quarter of 2027, while eloralintide’s Phase 3 program is still enrolling. This comparison is written for researchers deciding between the eloralintide 10 mg research vial and the retatrutide research vial, and it treats both as laboratory materials rather than treatments.

Eloralintide vs Retatrutide at a Glance

Parameter (October 2026)EloralintideRetatrutide
DeveloperEli Lilly (LY3841136)Eli Lilly
MechanismOnce-weekly amylin receptor agonist designed to preferentially activate AMY1ROnce-weekly GIP, GLP-1 and glucagon triple-hormone-receptor agonist
StatusInvestigational; Phase 3 ENLIGHTEN trials enrolling, estimated completion Feb 2028 to July 2030Investigational; Phase 3 TRIUMPH results reported at 80 weeks; BLA submission planned Q1 2027
Longest published trial48 weeks (Phase 2, no type 2 diabetes)80 weeks (TRIUMPH-1, TRIUMPH-2 and TRIUMPH-3); 104 weeks for 12 mg in a BMI ≥35 subgroup
Weight change at 48 weeks, no type 2 diabetes−20.1% at 9 mg, efficacy estimand; placebo −0.4%−24.2% at 12 mg, LS-mean; placebo −2.1%
Weight change at 80 weeksNo data−28.3% at 12 mg (TRIUMPH-1, no type 2 diabetes); −20.8% at 12 mg (TRIUMPH-2, type 2 diabetes)
Weekly doses studied1, 3, 6, 9 mg (Phase 2); 12 mg (Phase 1b)1, 4, 8, 12 mg (Phase 2); 4, 9, 12 mg (Phase 3)
Discontinuation for adverse events0% to 21.4% by arm, pooled 10.1%, placebo 7.7% (Phase 2)6% to 16% vs 0% placebo (Phase 2); 4.1% to 11.3% vs 4.9% (TRIUMPH-1)
Human combination dataWith tirzepatide (EloraTZP Phase 2b)None with eloralintide
Research format at PSPeptidesSingle 10 mg lyophilized vialResearch vial (see product page)

Sources: Lilly press release, Nov 6, 2025; Billings et al., The Lancet 2025; Jastreboff et al., N Engl J Med 2023; Lilly press releases of May 21, July 23 and Sept 29, 2026; Lilly, “What to know about eloralintide”; Lilly Trials pages for ENLIGHTEN-1 and ENLIGHTEN-2.

Three caveats run through every row of this eloralintide vs retatrutide table. The eloralintide numbers come from a 263-person Phase 2 trial with arms of 24 to 54 people, while retatrutide’s come from a 338-person Phase 2 trial and a Phase 3 program reported at 80 weeks; the durations differ beyond week 48; and the placebo responses differ. Each section below restates those conditions next to the numbers it quotes.

Eloralintide vs retatrutide comparison: amylin receptor agonist against triple incretin agonist trial data

Two Mechanisms: Amylin Receptor Agonist Against Triple Incretin Agonist

The eloralintide vs retatrutide contrast starts at the receptor. Lilly describes eloralintide as “designed to preferentially activate the amylin 1 receptor (AMY1R)” and notes that in clinical trials “it was self-injected once weekly” (Lilly, What to know about eloralintide). Retatrutide is a triple-hormone-receptor agonist, the class named in the title of its Phase 2 paper, acting at the GIP, GLP-1 and glucagon receptors (Jastreboff et al., N Engl J Med 2023).

That difference is why the two are not interchangeable in a research design: one probes the amylin pathway, the other the incretin and glucagon pathways, so an eloralintide vs retatrutide study is a comparison of pathways rather than of potencies. The receptor-level detail for eloralintide, including the caveat that its AMY1R preference is a potency preference rather than true selectivity, is covered in the eloralintide research guide; the retatrutide guide does the same for the triple agonist.

Matched-Duration Efficacy: 48 Weeks in Adults Without Type 2 Diabetes

The fairest eloralintide vs retatrutide comparison uses the two 48-week Phase 2 trials, because both enrolled adults with obesity or overweight and no type 2 diabetes and both ran for the same duration. The eloralintide trial randomised 263 participants across seven arms; the retatrutide trial randomised 338 across its dose arms and placebo. Even so, the placebo responses differed (−0.4% against −2.1%) and the estimands are not identical, so the table below is a side-by-side listing, not a head-to-head result.

Trial (48 weeks, no type 2 diabetes)Weekly armWeek-48 weight changePlacebo
Eloralintide Phase 2 (efficacy estimand)1 mg−9.5%−0.4%
Eloralintide Phase 2 (efficacy estimand)3 mg−12.4%−0.4%
Eloralintide Phase 2 (efficacy estimand)6 mg−17.6%−0.4%
Eloralintide Phase 2 (efficacy estimand)9 mg−20.1%−0.4%
Eloralintide Phase 2 (efficacy estimand)6→9 mg−19.9%−0.4%
Eloralintide Phase 2 (efficacy estimand)3→6→9 mg−16.4%−0.4%
Retatrutide Phase 2 (LS-mean change)1 mg−8.7%−2.1%
Retatrutide Phase 2 (LS-mean change)4 mg−17.1%−2.1%
Retatrutide Phase 2 (LS-mean change)8 mg−22.8%−2.1%
Retatrutide Phase 2 (LS-mean change)12 mg−24.2%−2.1%

Sources: Lilly press release, Nov 6, 2025 (eloralintide, 263 participants); Jastreboff et al., N Engl J Med 2023 (retatrutide, 338 participants). Cross-trial figures are indicative only.

Read at the top dose of each trial, the eloralintide vs retatrutide gap is about four percentage points in retatrutide’s favour (−24.2% against −20.1%), and it narrows only slightly once each trial’s own placebo response is taken into account. The eloralintide figure is the efficacy estimand reported in the Lilly press release of November 6, 2025; the treatment-regimen estimand, which keeps participants who stopped dosing, was −17.5% for the same 9 mg arm (Billings et al., The Lancet 2025).

Lilly’s ObesityWeek 2025 presentation adds two eloralintide details: in a DXA substudy, 60 to 70% of the weight lost was fat, and up to 57% of participants lost at least 20% of body weight (Hsia, Billings and Bays, ObesityWeek 2025). Neither finding had an active comparator, so neither supports a claim of superiority over retatrutide.

The escalation arms are worth a separate look. Eloralintide’s 6→9 mg and 3→6→9 mg arms finished at −19.9% and −16.4%, both below the fixed 9 mg arm, whereas the retatrutide Phase 2 figures above are reported by assigned dose. Comparing a slow-escalation eloralintide arm with a top-dose retatrutide arm would stack the deck, so the fixed-dose rows are the ones to set side by side.

Eloralintide and retatrutide 48-week Phase 2 weight change by dose arm with placebo values

Retatrutide Beyond 48 Weeks: TRIUMPH-1 and TRIUMPH-2

Retatrutide’s Phase 3 results extend the eloralintide vs retatrutide comparison to a duration eloralintide has not yet reached. In TRIUMPH-1, adults with obesity and no type 2 diabetes lost −19.0%, −25.9% and −28.3% (−70.3 lb) at 80 weeks on 4, 9 and 12 mg, and the 12 mg arm reached −30.3% at 104 weeks in a BMI ≥35 subgroup (Lilly press release, May 21, 2026).

Retatrutide Phase 3 trialPopulationDuration4 mg9 mg12 mgPlacebo
TRIUMPH-1Obesity, no type 2 diabetes80 weeks−19.0%−25.9%−28.3% (−70.3 lb)−2.2%
TRIUMPH-1, BMI ≥35 subgroupObesity, no type 2 diabetes104 weeks——−30.3%—
TRIUMPH-2Type 2 diabetes with obesity or overweight80 weeks−12.7%−19.1%−20.8%−4.0%
TRIUMPH-3Severe obesity with established cardiovascular disease, with or without type 2 diabetes80 weeksNot studied−21.6%−22.6%−3.2%
Eloralintide monotherapy, for comparisonAnyBeyond 48 weeksNo dataNo dataNo data—

Sources: Lilly press release, May 21, 2026 (TRIUMPH-1); Lilly press release, Sept 29, 2026 (TRIUMPH-2); Lilly press release, July 23, 2026 (TRIUMPH-3). All efficacy estimand.

TRIUMPH-2 matters for a different reason: it is a type 2 diabetes population, where weight-loss figures run lower than in non-diabetic trials, and its −20.8% at 12 mg against −4.0% placebo (Lilly press release, Sept 29, 2026) should only ever be set beside other diabetic-population data. Eloralintide’s only diabetic-population results come from the EloraTZP trial, which is covered in the eloralintide vs tirzepatide comparison, and they ran 48 weeks, not 80.

TRIUMPH-3 added a third population: adults with severe obesity and established cardiovascular disease, who lost −21.6% on 9 mg and −22.6% on 12 mg against −3.2% on placebo over 80 weeks (Lilly press release, July 23, 2026). Eloralintide has no published results in a cardiovascular-disease population.

Tolerability: Nausea by Arm and Discontinuation for Adverse Events

Eloralintide’s Phase 2 paper itemises nausea for every arm, which makes the eloralintide vs retatrutide tolerability picture lopsided. For retatrutide, gastrointestinal events were the most common adverse events and were dose-related (Jastreboff et al., N Engl J Med 2023); discontinuation for adverse events is the one measure set out for both below.

Trial and armNauseaDiscontinued for adverse events
Eloralintide Phase 2, placebo (n=53)13.5%7.7%
Eloralintide Phase 2, 1 mg (n=28)11.1%11.1%
Eloralintide Phase 2, 3 mg (n=24)13.0%0%
Eloralintide Phase 2, 6 mg (n=28)64.3%21.4%
Eloralintide Phase 2, 9 mg (n=54)33.3%7.4%
Eloralintide Phase 2, 6→9 mg (n=24)54.2%8.3%
Eloralintide Phase 2, 3→6→9 mg (n=52)25.0%11.5%
Eloralintide Phase 2, all eloralintide arms pooled32.7%10.1%
Retatrutide Phase 2, all retatrutide arms (48 weeks)GI events most common, dose-related6% to 16% vs 0% placebo
Retatrutide TRIUMPH-1, 4 / 9 / 12 mg (80 weeks)Not given in the release4.1% / 6.9% / 11.3% vs 4.9% placebo

Sources: Billings et al., The Lancet 2025 (safety population N=260; arms of 24 to 54 are small and per-arm rates are noisy); Jastreboff et al., N Engl J Med 2023; Lilly press release, May 21, 2026.

Two things stand out. Eloralintide at 1 and 3 mg had nausea no higher than placebo, and its slow 3→6→9 mg escalation kept nausea at 25.0% while still reaching 9 mg; serious adverse events were 5.8% on placebo and 5.3% pooled, with no deaths. Retatrutide’s 80-week discontinuation rates of 4.1% to 11.3% are low for the weight loss delivered, but they come from a far larger Phase 3 population and a longer trial.

On the eloralintide vs retatrutide tolerability question, then, the honest answer is that the two datasets measure different things over different periods, and neither set of percentages can be ranked against the other. The eloralintide side-effects review and retatrutide results summary hold the full event tables.

Eloralintide nausea by Phase 2 arm and retatrutide discontinuation rates compared

Dosing Patterns: Weekly Injections, Dose Ranges and Escalation

Both peptides are given once weekly by subcutaneous injection, and both were studied as fixed doses with escalation arms, but the eloralintide vs retatrutide dose ranges differ. Eloralintide’s Phase 2 doses were 1, 3, 6 and 9 mg, with a 6→9 mg arm that held 6 mg for 20 weeks before 28 weeks at 9 mg, and a 3→6→9 mg arm that stepped every four weeks before 40 weeks at 9 mg.

Twelve milligrams of eloralintide weekly was tested only in the 12-week Phase 1b study, without titration, and never carried into Phase 2. Retatrutide’s Phase 2 arms were 1, 4, 8 and 12 mg, and its Phase 3 program used 4, 9 and 12 mg, so the top retatrutide dose is a third higher in milligrams than the top eloralintide Phase 2 dose, a number that says nothing about relative potency across two receptor classes.

Retatrutide’s escalation steps are covered in the retatrutide dosage guide. For eloralintide, the trial doses map neatly onto a 10 mg vial: reconstituted in 1.0 mL of bacteriostatic water the vial is 10 mg/mL, so 3 mg is 30 units, 6 mg is 60 units and 9 mg is 90 units on a U-100 syringe, and the eloralintide dosage guide gives every schedule and vial count.

Development Status: BLA in Q1 2027 Against Phase 3 Readouts From 2028

Retatrutide’s regulatory path is dated: Lilly plans a BLA submission in Q1 2027 on the strength of the TRIUMPH program. Eloralintide’s is not. Lilly’s page says only that it “is currently investigating eloralintide in Phase 3 trials,” and its forward-looking statement gives “no assurance” of approval; no Phase 3 doses, readout dates or filing timeline have been disclosed.

What the registry shows is the schedule of the two largest eloralintide trials: ENLIGHTEN-1 (NCT07321886), about 1,980 participants without type 1 or type 2 diabetes, started January 1, 2026 with an estimated completion of July 2030, and ENLIGHTEN-2 (NCT07282600), about 1,035 participants with type 2 diabetes, started December 15, 2025 with an estimated completion of February 2028. Any eloralintide vs retatrutide timeline therefore shows retatrutide well ahead: a filing planned for early 2027 against Phase 3 completions no earlier than 2028.

Which Peptide to Research for Which Question

Research questionBetter-documented candidateWhy
Amylin receptor pharmacologyEloralintideDesigned to preferentially activate AMY1R; 48-week monotherapy data at −20.1%
GIP, GLP-1 and glucagon pathway pharmacologyRetatrutideTriple-hormone-receptor agonist with Phase 2 and Phase 3 datasets
48-week benchmark without type 2 diabetesEither−20.1% at 9 mg (placebo −0.4%) against −24.2% at 12 mg (placebo −2.1%); different estimands
Outcomes beyond 48 weeksRetatrutide80-week and 104-week data; eloralintide has none
Type 2 diabetes populationRetatrutide for 80-week dataTRIUMPH-2 −20.8% at 12 mg; eloralintide’s diabetic data are 48-week EloraTZP arms
Slow-escalation tolerability modellingEloralintide3→6→9 mg arm: 25.0% nausea, 1.9% vomiting
Body-composition substudyEloralintideDXA: 60–70% of lost weight was fat, no comparator
Pairing with tirzepatideEloralintideEloraTZP Phase 2b exists
Pairing the two with each otherNeitherNo human study has combined them

Decision guidance for laboratory planning, derived from the sources in the References list; not treatment guidance.

For a laboratory that needs the amylin pathway, the eloralintide vs retatrutide question answers itself, and the reverse is true for incretin work. Where the question is simply “which has the deeper dataset,” retatrutide wins on duration and population size, and eloralintide wins on per-arm tolerability detail and body-composition data.

No Human Trial Has Combined Them

As of October 2026 no human study has combined eloralintide with retatrutide, semaglutide or cagrilintide; the only combination Lilly has tested is eloralintide with tirzepatide, in a type 2 diabetes population, and the company plans Phase 3 studies of that co-formulation by the end of 2026. A research protocol that pairs eloralintide with retatrutide therefore has no clinical template for dose pairing, sequencing or tolerability, and our retatrutide vs tirzepatide comparison is the closest documented reference for retatrutide alongside another incretin agent.

Eloralintide and retatrutide lyophilized research vials with certificates of analysis

Research Vials for Both Peptides

PSPeptides stocks the eloralintide 10 mg lyophilized vial alongside retatrutide, and both are synthesized in a cGMP-compliant facility in Temecula, California, with every lot tested by independent accredited laboratories: HPLC purity at a 99%+ minimum, mass-spectrometry identity, and endotoxin, sterility, heavy-metal and fentanyl screening, as set out on the certifications page. Current pricing and each lot’s certificate of analysis are on each product page.

The free peptide calculator converts any trial dose to syringe units for either peptide, and bacteriostatic water and U-100 insulin syringes can be added to the same order. Orders placed before 2 PM EST ship the same day, US shipping is free, and card, Afterpay and Klarna payments are accepted for both vials.

Buy eloralintide 10 mg · Buy retatrutide

Frequently Asked Questions on Eloralintide and Retatrutide

Which produced more weight loss at 48 weeks, eloralintide or retatrutide?

In separate 48-week Phase 2 trials of adults without type 2 diabetes, retatrutide 12 mg produced −24.2% against a −2.1% placebo response, and eloralintide 9 mg produced −20.1% against −0.4% on the efficacy estimand. The trials differ in placebo response, estimand and size, so the eloralintide vs retatrutide comparison is indicative rather than head-to-head.

Can eloralintide and retatrutide be combined?

No human study has combined them as of October 2026. The only eloralintide combination Lilly has tested is with tirzepatide, in the EloraTZP Phase 2b trial, so a paired protocol would have no clinical reference for doses or tolerability.

Which is closer to approval, retatrutide or eloralintide?

Retatrutide, by a wide margin: Lilly plans a BLA submission in Q1 2027 after the 80-week TRIUMPH trials. Eloralintide is in Phase 3 trials with estimated completion dates between February 2028 and July 2030, and neither peptide is approved by any regulator.

How do the dose ranges compare?

Eloralintide was studied at 1 to 9 mg once weekly in Phase 2, with 12 mg weekly tested only in a 12-week Phase 1b study. Retatrutide was studied at 1 to 12 mg once weekly in Phase 2 and at 4, 9 and 12 mg in Phase 3, so its range runs higher, although milligram doses of two different receptor agonists are not equivalent.

References

  1. Eli Lilly press release, Nov 6, 2025 — “Lilly’s selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight.” https://investor.lilly.com/node/53246
  2. Billings LK, Hsia S, Bays H, et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. The Lancet. 2025;406(10520):2631–2643. https://doi.org/10.1016/S0140-6736(25)02155-5
  3. Hsia S, Billings LK, Bays H. Eloralintide Phase 2 study in adult participants with obesity or overweight. Symposium presentation, ObesityWeek 2025 (Eli Lilly). https://assets.ctfassets.net/mpejy6umgthp/1SxVs7VHGLcnTF2V1Drf8w/936ff7e537ab94a8e92495efa09a0f23/VV-ELORAPT3_OW2025_HSIA_BILLINGS_BAYS_ELORALINTIDE_SYMPOSIUM_DV-033298_V3.2.pdf
  4. Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023. https://doi.org/10.1056/NEJMoa2301972
  5. Eli Lilly press release, May 21, 2026 — retatrutide TRIUMPH-1. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss
  6. Eli Lilly press release, Sept 29, 2026 — retatrutide TRIUMPH-2. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-substantial-weight
  7. Eli Lilly press release, July 23, 2026 — retatrutide TRIUMPH-2 and TRIUMPH-3. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional
  8. Eli Lilly, “What to know about eloralintide” (last updated September 2026). https://www.lilly.com/news/stories/what-to-know-about-eloralintide
  9. ClinicalTrials.gov — ENLIGHTEN-1 (NCT07321886) https://clinicaltrials.gov/study/NCT07321886; ENLIGHTEN-2 (NCT07282600) https://clinicaltrials.gov/study/NCT07282600. Accessed October 12, 2026.

All PSPeptides products are sold exclusively for research and laboratory use.